- Global Pharma News & Resources

Triptorelin Market Size Worth US$ 670 Million | CAGR 5.2% By 2026, Says Coherent Market Insights

SEATTLE, April 08, 2021, (PHARMIWEB) — Global Triptorelin Market

Gonadotropin-releasing hormone (GnRH) agonists are more effective and safe compared to estrogens and anti-androgens used to attain medical castration. GnRH agonists offer slow-release formulations that aids in enhancing quality of life of patients and reducing related expenditures. It is more likely that prostate cancer progresses with increasing testosterone hormone. It is often recommended to remove testicles or use medication therapy to halt the production of testosterone. Triptorelin is GnRH agonists that can halt the production of testosterone, which decreases the level of testosterone, thereby restricting the development of prostate cancer.

Triptorelin is a decapeptide analogue of Luteinising Hormone-Releasing Hormone (LHRH, also called gonadotropin-releasing hormone [GnRH]) and finds application in hormone dependent advanced prostate cancer therapy. According to National Institute for Health and Care Excellence (NICE), in May 2013, the licensed indications for luteinising hormone-releasing hormone (LHRH) agonist: triptorelin was extended to include two new indications for prostate cancer: first in neoadjuvant treatment before radiotherapy in high-risk localized or locally advanced disease and second in adjuvant treatment to radical prostatectomy in locally advanced disease at high risk of progression. Triptorelin is administrated intramuscularly or subcutaneously.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@

Triptorelin can also be effective in the treatment of Central Precocious Puberty (CPP) in children two years of age or above. Increasing approval and launch of novel products is expected to boost growth of the market. For instance, in July 2017, the U.S. Food and Drug Administration (FDA) approved Arbor Pharmaceuticals’: Triptodur for the treatment of central precocious puberty in pediatric patients. The approval was given on the grounds of a phase 3 clinical trial (Efficacy, Safety, and Pharmacokinetics [PK] of Triptorelin 6-month Formulation in Patients with Central Precocious Puberty) that evaluated prepubertal luteinizing hormone levels using triporelin therapy. Use of Triptodur led to increase in pre-pubertal luteinizing hormone (LH) levels by 93% in the participants and the pre-pubertal luteinizing hormone (LH) suppression was maintained at 12 months by 98% of patients.

The global triptorelin market size was valued at US$ 426.4 Mn in 2017, and is expected to witness a CAGR of 5.2% over the forecast period (2018 – 2026).

Global Triptorelin Market Share, By Product Type2018 & 2026

Source: Coherent Market Insights Analysis (2018)

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @

Extended use of triptorelin in the treatment of other disorders is expected to boost growth of the market during the forecast period

Triptorelin is a first-line hormonal therapy that can be effective and safe in the treatment of non-metastatic or metastatic prostate cancer. Increasing R&D has also been done to evaluate the efficacy of triptorelin in treatment of various diseases. For instance, in May 2018, Immune System Regulation AB began a study to assess the efficacy of triptorelin in HIV-1 reservoir reduction in Antiretroviral Therapy (ART) treated HIV-1 infected patients and the study is currently in phase II clinical stage. Moreover, in July 2017, National Cancer Institute (NCI), Naples sponsored a study to assess the efficacy and safety of Tamoxifen, Letrozole and Letrozole + Zoledronate in the treatment of bone loss in breast cancer patients and the study is currently in phase III clinical stage. Successful completion of these trials and subsequent launch of these therapies is expected to boost growth of the market during the forecast period.

Triptorelin is highly effective in the suppression of gonadotropin in Central Precocious Puberty (CPP) in children, which further increases its demand. For instance, according to data published in the Scientific World Journal, in May 2012, triptorelin 11.25 mg per 90 days efficiently suppressed the pituitary-gonadal level in children with CPP from first administration.

Key players in the market are focused on R&D in androgen deprivation therapy with triptorelin to decrease development of salivary gland cancer expressing androgen receptors. For instance, in January 2016, Debiopharm International SA collaborated with European Organization for Research and Treatment of Cancer (EORTC) to investigate Triptorelin for the treatment of salivary gland cancer. Under the collaboration, Debiopharm International SA will supply triptorelin pamoate 3.75 mg 1-month formulation to patients suffering from salivary gland cancer participating in a clinical study sponsored by EORTC. During the clinical study, researchers are expected to assess the efficacy and safety of androgen chemotherapy versusandrogen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptors-expressing salivary gland cancers.

View Press Release For More Information @

Global Triptorelin Market Share, By Application2018 & 2026

Source: Coherent Market Insights Analysis (2018)

High incidence of prostate cancer is expected to boost demand for triptorelin

High prevalence of prostate cancer is expected to boost growth of the market. Triptorelin can be used in the treatment of prostate cancer as it has the ability to restrict testosterone production to halt the progression of cancer cells. For instance, according to the World Cancer Research Fund (WCRF) International, 2012, over 1.1 million cases of prostate cancer were recorded, accounting for around 8% of all new cancer cases worldwide. Furthermore, around 68% of prostate cancer cases were registered in the developed economies. Highest incidence of prostate cancer was reported in Oceania and North America, while lowest incidence was reported in Asia and Africa.

Moreover, according to the Cancer Research U.K., in 2015, around 47,151 new cases of prostate cancer were registered in the U.K. Furthermore, prostate cancer accounted for 13% of the total cancer cases in the U.K., in 2015. Prostate cancer is the second-most common cause of cancer deaths among males in the U.K. in 2014, accounting for 13% of all cancer deaths among males. According to the same source, in 2014, around 11,287 prostate cancer deaths were recorded among males in the U.K. The crude mortality rate shows that there were 36 prostate cancer deaths for every 100,000 males in the country.

Key players operating in triptorelin market include, Chengdu Tiantaishan Pharmaceutical Co., Ltd., Tecnofarma, Ipsen, Bachem, Ferring Pharmaceuticals Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Debiopharm Group, Teva Pharmaceutical Industries Ltd. (Actavis Specialty Pharmaceuticals Co.), and Arbor Pharmaceuticals, LLC.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 08-Apr-2021